Bristol-Myers Squibb Stock
Bristol-Myers Squibb Stock
The Bristol-Myers Squibb stock is trending slightly upwards today, with an increase of €0.37 (0.670%) compared to yesterday's price.
With 22 Buy predictions and 3 Sell predictions Bristol-Myers Squibb is one of the favorites of our community.
As a result the target price of 60 € shows a slightly positive potential of 8.15% compared to the current price of 55.48 € for Bristol-Myers Squibb.
For the coming years our community has positive and negative things to say abot the Bristol-Myers Squibb stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Business model" there were negative voices in the community.
Pros and Cons of Bristol-Myers Squibb in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bristol-Myers Squibb vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | 0.670% | -3.553% | 9.324% | 39.202% | 19.609% | -1.589% | -3.231% |
| AbbVie Inc. | 0.050% | 2.411% | -0.276% | 26.519% | 10.285% | 55.715% | 123.645% |
| Biogen Inc. | -0.780% | -2.268% | 1.226% | 60.181% | 17.905% | -29.328% | -38.833% |
| Zoetis Inc. A | -0.400% | -0.971% | -1.360% | -49.167% | -39.195% | -62.558% | -61.166% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
Bristol Myers Squibb Co. (BMY) has reported its Q2 2025 financial results as of March 31, 2025. The company's current financial position shows a mixed trend with both positive and challenging indicators.
Key Findings: * Revenue decreased to $11.201 billion from $11.865 billion in the same quarter last year * Net profit significantly improved to $2.456 billion compared to a loss of $11.911 billion in Q2 2024 * Cash and cash equivalents increased to $10.875 billion from $9.334 billion as of March 31, 2024
Overall Trend: Mixed, with improving profitability but declining revenue.
Comments
Bristol Myers Squibb (BMY) is now covered by Piper Sandler. They set an "overweight" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (BMY) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".
Show more
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (BMY) is now covered by Roth Capital. They set a "buy" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat